Effect of Sodium Tanshinone IIA Sulfonate in Perioperative Period on the Prognosis of Patients with CHD and Angina Pectoris after Interventional Therapy
ZHU Yujiang, et al
The Second Affiliated Hospital of Xi'an Medical University, Shaanxi Xi'an 710038, China
Abstract：Objective: To study the effect of application of sodium tanshinone IIA sulfonate in perioperative period on the prognosis of patients with coronary heart disease (CHD) and angina pectoris after interventional therapy. Methods: 94 cases of CHD with coronary intervention (PCI) treated by coronary intervention (PCI) were divided into the control group and the study group with 47 cases each by random number table in March 2013 to March 2017. The control group was treated with conventional therapy such as clopidogrel and aspirin during the perioperative period. The study group was treated with routine treatment with tanshinone IIA A sulfonate. Blood rheology, platelet membrane glycoproteins, inflammatory factors and brain natriuretic peptide (BNP) levels, short-term prognosis and adverse drug reactions were compared between the two groups before and after treatment. Results: After treatment, the blood rheological indicators were significantly decreased in the two groups (P < 0.05), and the blood viscosity, high / low shear blood viscosity, the maximum platelet aggregation rate and fibrinogen levels were significantly lower in the study group than in the control group (P < 0.05); the levels of CD62p, CD63, PAC-1, CRP, IL-6 and BNP were significantly decreased, and CD42b levels were increased significantly in the two groups (P < 0.05), and the above levels in the study group were lower than those in the control group (P < 0.05). The recurrence rate of angina pectoris in the study group was significantly lower than that in the control group during follow-up period (P < 0.05), and there was no significant difference in the incidence of adverse drug reactions between the two groups (P > 0.05). Conclusion: The application of sodium tanshinone IIA sulfonate in perioperative period of PCI can effectively improve the blood rheological indexes, play an antiplatelet role, promote the recovery of tissue injury, relieve inflammation, and improve the cardiac function in patients with coronary heart disease and angina pectoris, without increasing adverse reactions, and the short-term prognosis is good.
朱玉江, 邢晓龙, 王西辉. 围手术期应用丹参酮ⅡA磺酸钠对冠心病心绞痛介入治疗患者术后预后的影响[J]. 河北医学, 2017, 23(8): 1284-1287.
ZHU Yujiang, et al. Effect of Sodium Tanshinone IIA Sulfonate in Perioperative Period on the Prognosis of Patients with CHD and Angina Pectoris after Interventional Therapy. 河北医学, 2017, 23(8): 1284-1287.
2017, Vol. 23 
冀公网安备13080202000677号